EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study

Scott F Huntington iD, Stephen J Schuster, Wei Ding iD, Amber B Koehler, Danielle M Brander, Allison C Rosenthal iD, Jose F Leis, Han W Tun, Muhamad Alhaj Moustafa, Madiha Iqbal iD, Wei He, Albert S Kearney und 3 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26888 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Scott F Huntington und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase inhibitors (BTKi) with inhibitors of mammalian target of rapamycin (mTOR) and immunomodulatory agents (IMiD). We conducted a phase 1, open‐label study at five centers in USA to evaluate the safety of triplet BTKi/mTOR/IMiD therapy. Eligible patients were adults aged 18 years or older with relapsed/refractory CLL, B cell NHL, or Hodgkin lymphoma. Our dose escalation study used an accelerated titration design and moved sequentially from single agent BTKi (DTRMWXHS‐12), doublet (DTRMWXHS‐12 + everolimus), and then to triplet therapy (DTRMWXHS‐12 + everolimus + pomalidomide). All drugs were dosed once daily on days 1–21 of each 28‐day cycle. The primary goal was to establish the recommended phase 2 dose of the triplet combination. Between September 27, 2016, and July 24, 2019, a total of 32 patients with a median age of 70 years (range 46 to 94 years) were enrolled. No MTD was identified for monotherapy and the doublet combination. The MTD for the triplet combination was determined to be DTRMWXHS‐12 200 mg + everolimus 5 mg + pomalidomide 2 mg. Responses across all studied cohorts were seen in 13 of 32 (41.9%). Combining DTRMWXHS‐12 with everolimus and pomalidomide is tolerable and shows clinical activity. Additional trials could confirm benefit of this all‐oral combination therapy for relapsed/refractory lymphomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphomaAdultAgedAged, 80 and overHumansMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsEverolimusNeoplasm Recurrence, LocalProtein Kinase InhibitorsSirolimusTOR Serine-Threonine KinasesTreatment OutcomeTyrosine Kinase InhibitorsThalidomideOrganic Chemicals

Substanzen

EverolimusProtein Kinase InhibitorsSirolimusTOR Serine-Threonine KinasesTyrosine Kinase InhibitorspomalidomideThalidomideDTRMWXHS-12Organic Chemicals

Autor:innen und Institutionen

  • Section of Hematology, Yale University, New Haven, Connecticut, USA.
  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Duke University Medical Center, Durham, North Carolina, USA.
  • Division of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Scott F Huntington, Wei Ding, Allison C Rosenthal, Madiha Iqbal

Zitieren

APA

Huntington, S. F., Schuster, S. J., Ding, W., Koehler, A. B., Brander, D. M., Rosenthal, A. C., Leis, J. F., Tun, H. W., Moustafa, M. A., Iqbal, M., He, W., Kearney, A. S., McKinlay, T. P., Gui, M., & Mato, A. R. (2023). DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. https://doi.org/10.1002/ajh.26888

Vancouver

Huntington SF, Schuster SJ, Ding W, Koehler AB, Brander DM, Rosenthal AC, et al. DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. 2023. doi:10.1002/ajh.26888

BibTeX
@article{Huntington2023,
  author = {Huntington, Scott F and Schuster, Stephen J and Ding, Wei and Koehler, Amber B and Brander, Danielle M and Rosenthal, Allison C and Leis, Jose F and Tun, Han W and Moustafa, Muhamad Alhaj and Iqbal, Madiha and He, Wei and Kearney, Albert S and McKinlay, Timothy P and Gui, Min and Mato, Anthony R},
  title = {DTRMWXHS ‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26888}
}
Kostenlos starten →